By Christina Grube (MASS TORT NEWS) Yesterday, California Superior Court Judge Evelio Grillo denied a motion to dismiss all plaintiff experts in the California Zantac JCCP (In Re: Ranitidine Product Cases, JCCP No. 5150), allowing the first Zantac bellwether trial to proceed this July. Judge Grillo denied the defendant GSK’s (formerly GlaxoSmithKline) motion to exclude … [Read more...] about California Judge strikes down GSK motion; first Zantac trial to proceed
Zantac
JPML Breakdown: All Rulings Made at First 2023 Hearing
By Christina Grube (MASS TORT NEWS) The JPML held their first 2023 hearing on January 26 at the Southern District of Florida Wilkie D. Ferguson, Jr. U.S. Courthouse in Miami, FL. Five of the eight cases with designated oral arguments have received centralization, creating five new MDLs. Full rundown on all JPML decisions below: Decisions with Oral Arguments: MDL No. … [Read more...] about JPML Breakdown: All Rulings Made at First 2023 Hearing
Brent Wisner Comments on Zantac Judgment Dismissing Plaintiff Experts
West Palm Beach County Historic Courthouse; West Palm Beach, FL Christina Grube, MTN Correspondent (MASS TORT NEWS) Judge Robin L. Rosenberg granted the defendants summary judgment in MDL 2924 for Zantac, resulting in the dismissal of plaintiff experts. In the 341 page judgment, Rosenburg ruled that the studies of animals which plaintiff experts used to support … [Read more...] about Brent Wisner Comments on Zantac Judgment Dismissing Plaintiff Experts
Motion By Plaintiff Leadership Undermines Effectiveness of Zantac MDL?
By Christina Grube Updated 11/29/22 (MASS TORT NEWS) A recent motion by Plaintiff leaders in Zantac MDL 2924 may serve to undermine the effectiveness of the MDL. In January, U.S. District Judge Robin Rosenburg approved the request by Plaintiff leadership to reduce the number of cancers from 10 to 5, removing certain cancers (breast, prostate, colorectal, kidney, and … [Read more...] about Motion By Plaintiff Leadership Undermines Effectiveness of Zantac MDL?
Baum Hedlund Sues FDA to Force Release of Agency Documents Related to ‘Flawed’ Zantac Study
Case captioned: James E. Goetz v. U.S. Food and Drug Administration (Case 3:22-cv-04768-TSH). August 26, 2022 - (MASS TORT NEWS) The Baum Hedlund Aristei & Goldman law firm filed a lawsuit against the U.S. Food and Drug Administration (FDA) last to compel the agency to release documents regarding an agency-sponsored study on Zantac which “has a number of alarming and … [Read more...] about Baum Hedlund Sues FDA to Force Release of Agency Documents Related to ‘Flawed’ Zantac Study
NEW MDL LITIGATION ON THE HORIZON
By Brandon Salter Michael Brady Lynch Firm August 1, 2022 (Mass Tort News) - 2022 has been a momentous year for Multi-district Litigation, particularly in pharmaceutical MDLs such as Zantac, Valsartan, Elmiron, Taxotere, Nexium & Prilosec. It is expected that some of these cases will go to trial in the year 2023; however, the best is yet to come with new … [Read more...] about NEW MDL LITIGATION ON THE HORIZON
A Forward-Looking Perspective on Mass Tort Practice
As with most things, the future of mass torts will likely mimic its past. Cancer cases, like those associated with tobacco and asbestos in the past, are driving current and future mass tort litigation. New and ongoing litigation continues for products such as: Zantac Roundup Talc Valsartan Sunscreen PFAS Metformin CPAP With technological and scientific … [Read more...] about A Forward-Looking Perspective on Mass Tort Practice
ZANTAC MDL 2924-Recent Rulings and Overall Status
Including comments by Brent Wisner, Baum Hedlund. MASS TORT NEWS January 18, 2021 Washington, DC In Re: Zantac (Ranitidine) Products Liability Litigation MDL 2924 court website JPML Initial Zantac Transfer Order, Feb. 6, 2020 By Mark A. York, Editor (MassTortNews.org) United States consumers are learning more and more that healthcare manufacturing oversight has failed … [Read more...] about ZANTAC MDL 2924-Recent Rulings and Overall Status
Zantac Litigation Overview
Article Provided by Brenden Leydon Attorney at Wocl Leydon LLC The litigation over the harmful effects of Zantac (generic name is Ranitidine) is just getting underway, and it looks like it will lead to a significant number of cases. What is Zantac/Ranitidine? Ranitidine is an antacid which belongs to a class of drugs known as histamine-2 receptor agonists (H2 blockers). … [Read more...] about Zantac Litigation Overview
FDA Issues Recall Statement On All Zantac (Ranitidine) Products
FDA NEWS RELEASE FDA Requests Removal of All Ranitidine Products (Zantac) from the Market FDA Advises Consumers, Patients and Health Care Professionals After New FDA Studies Show Risk The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the … [Read more...] about FDA Issues Recall Statement On All Zantac (Ranitidine) Products
